Most cancer vaccines to date have made use of common tumor antigens or allogenic cancer cell lines. The majority of tumor antigens may, however, be unique patient-specific antigens. Dendritic cells (DCs) are the most potent antigen-presenting cells known. The present report is a full-scale preclinical evaluation of autologous DCs transfected with autologous tumor-mRNA (tDCs) for vaccination in malignant melanoma. By using autologous tumor-mRNA, we intend to make the DCs present a broad spectrum of tumor-associated antigens relevant to each individual patient. Previously, we have described effective methods for mRNAtransfection into DCs by square-wave electroporation and for generating large numbers of DCs. Here, we demonstrate the ability of tDCs, made under full-scale vaccine conditions, to generate in vitro T-cell responses specific for antigens encoded by the transfected tumor-mRNA. T-cell proliferation assays demonstrated tDC-specific responses for all six patients tested. Responses were further studied by IFNg ELISPOT and Bioplex cytokine assays (two patients) and by experiments on isolated CD4 þ and CD8 þ T cells, including HLA-blockage (one patient). Moreover, we describe the results of extensive tumor-RNA analysis using Agilent Bioanalyser, a method that we have implemented in the clinical protocol. Based on this preclinical evaluation, a vaccine trial has been started.
D
espite numerous efforts to improve systemic treatment, curative therapy for malignant melanoma is still generally confined to surgical removal of local tumors at an early stage. For patients with disseminated malignant melanoma, the prognosis is dismal, with 5-year survival of about 6% and median survival of 7.5 months. 1 Observations indicating spontaneous immune responses in melanoma, and possible correlation with a favorable prognosis, 2, 3 have prompted various efforts of specific immune therapy. Most trials have made use of selected melanoma-associated antigens like MAGE-1 and -3, MART-1, and gp100. [4] [5] [6] Antigen-specific immune responses have been obtained, but none of the identified antigens is expressed in all melanomas, and initial vaccine responses are vulnerable to tumor escape due to loss of antigen expression.
Combining several antigens in a peptide cocktail may be helpful, but an even broader spectrum of vaccine antigens appears desirable. Numerous potential tumor antigens may arise from incidental mutations that are specific to each patient. As has been argued, the majority of immunogenic antigens may indeed be unique patientspecific tumor antigens, not previously defined and not represented in allogenic cancer cell lines. [7] [8] [9] In a melanoma study, it was found that none of the tumor-specific T-cell clones recognized any of the 10 HLA-matched peptides tested, derived from Melan-A/Mart-1, tyrosinase, gp100, and MAGE-3 proteins. 10 For the melanoma vaccine described here, we have selected complete autologous tumor-mRNA as the source of antigen. Thereby, we aim to elicit responses to a broad spectrum of tumor antigens, relevant to each individual patient. Screening of patients for tumor antigens or HLA alleles will not be necessary. The mRNA can encode multiple epitopes that can be effectively presented by different HLA alleles, possibly recruiting a wide spectrum of T-cell clones. In contrast to DNA and viral vectors, RNA is only transiently expressed and does not integrate into the host genome.
Dendritic cells (DCs) are known to be instrumental in the control of immunity and are acknowledged as the most potent antigen-presenting cells (APCs). 11 In several cancer forms, including malignant melanoma, DC-based vaccines are being investigated. [12] [13] [14] We have previously described an effective method for RNA transfection into DCs by square-wave electroporation. 15 Recently, we have also reported a reproducible method for generating large numbers of DCs that can be frozen in aliquots suitable for repeated vaccinations. 16 In this paper, we will consider the feasibility of a DC vaccine in advanced melanoma patients based on transfection with autologous tumormRNA. To our knowledge, no melanoma DC vaccine trial based on autologous tumor-RNA has been conducted to date. In a full-scale vaccine production, the limited mRNA source extracted from a solid tumor will be extensively diluted during electroporation. Immune responses can only be induced if the minute amounts of tumor-mRNA transfected into DCs result in protein production and presentation of new antigens on HLA class I/II on the DC surface. Furthermore, the presented autologous antigens need to be immunogenic in the context of possible tolerance and reduced immunocompetence in patients with advanced melanoma disease.
In this report, we demonstrate that DCs transfected with autologous melanoma-mRNA under full-scale vaccine conditions (tDCs), are in fact capable of initiating T-cell responses specific to antigens encoded by the transfected mRNA. Importantly, such responses were found in all six patients tested. We also present evidence suggesting spontaneous priming in two patients in vivo against antigens presented on tDCs after transfection. Furthermore, T-cell responses were characterized by multiple cytokine assays, tests of isolated CD4 þ and CD8 þ T cells and blockage of HLA class I and II. Moreover, we describe a method for extensive RNA analysis that we have implemented in the clinical protocol to evaluate RNA quality.
Materials and methods

Patient inclusion and tumor material
The study was approved by the Regional Committee for Medical Research Ethics and the Norwegian Medicines Agency, and was performed in accordance with the principles of the World Medical Association Declaration of Helsinki. All patients signed an informed consent prior to inclusion. The patients (aged 36, 43, 49, 58, 65 and 72 years) all had advanced melanoma disease (stage IV). Tumor biopsies were collected at The Norwegian Radium Hospital. All tumors used for RNA extraction were metastases confirmed by pathological examination to represent malignant melanoma. To minimize RNA degradation, the biopsies were immediately cut to a maximum diameter of 0.5 cm, put on ''RNA Later'' solution (Sigma-Aldrich, St Louis, MO, USA) and stored according to the manufacturer's protocol. The FM3 melanoma cell line was a gift from Dr A Kirkin, Danish Cancer Society, Copenhagen, Denmark.
RNA extraction
Extraction of autologous tumor-RNA was performed as a two-step procedure. First, total-RNA was extracted by use of Trizol, according to the manufacturer's protocol (Invitrogen Life Technologies, Carlsbad, CA). Briefly, tumor biopsies were taken directly from À801C, swiftly cut into tiny pieces by scalpels and then cut further on Trizol by a homogenizer (IKA Labortechnik, Staufen, Germany). After Trizol-chloroform extraction, total-RNA was dissolved in sterile H 2 O. Then mRNA purification was performed by use of polyT-coated magnetic beads (Genoprep mRNA Beads, Qiagen, Hilden, Germany), according to the manufacturer's protocol. The procedure was performed in a sterile hood inside a Good Manufacturing Practice laboratory facility (GMP-lab). RNA samples were stored at À801C.
RNA evaluation
The quality of all RNA preparations was controlled by electrophoresis on agarose gels stained by Gelstar (Cambrex Bio Science, Verviers, Belgium). For patients I, II, III, and V the RNA samples were also evaluated on an Agilent Bioanalyser instrument, using RNA 6000 Nano Reagents & Supplies (Agilent Technologies, Palo Alto, CA, USA). In the Bioanalyser, multiple RNA samples are analyzed simultaneously by gel electrophoresis in a micro-chip, as described elsewhere. 17 Analyses were carried out according to the manufacturer's protocol. The Bioanalyser allows for extensive RNA quality evaluation including identification of degraded RNA, rRNA/mRNA-fractions and DNA contamination. [18] [19] [20] High-molecular-mass DNA fragments may, however, not be detected, and combination with agarose gel is thus necessary for adequate purity control. 20 The Bioanalyser furthermore quantifies RNA (range 17-1000 ng/ml 20 
)
by calculating size and concentration of each separated band.
DC generation
DCs were generated in a mainly closed system, essentially as described earlier. 16 Briefly, peripheral blood mononuclear cells (PBMCs) were harvested by leukapheresis, and monocytes were enriched by immunomagnetic depletion of T cells and B cells. Enriched monocytes were then cultured for 5 days in CellGro DC medium (CellGenix, Freiburg, Germany) with granulocyte-macrophage-colony-stimulating factor (GM-CSF; 2500 U/ml) (Leucomax; Schering-Plough, Kenilworth, NJ, USA) and interleukin-4 (IL-4; 1000 U/ml) (CellGenix). DCs were cultured in Teflon bags (CellGenix). After 5 days for differentiation, the immature DCs were transfected with RNA. DCs were then cultured for 2 more days with cytokines facilitating maturation: IL-1b (10 ng/ml), IL-6 (1000 U/ml), tumor necrosis factor a (TNFa; 10 ng/ml) (CellGenix) and prostaglandin E 2 (1 mg/ml) (Sigma-Aldrich). Finally, matured DCs were frozen to À801C and transferred to liquid nitrogen. Through DC generation, cell quality was controlled by flow cytometry, sterility and viability testing. The methods and results of quality controls were essentially as described previously. 16 
DC transfection
Immature DCs were transfected with purified autologous tumor-mRNA. Transfection was performed essentially as described earlier, 16 using a BTX ECM 830 square-wave electroporator (Genetronics Inc., SanDiego, CA). Cells were transfected in a sterile hood inside the GMP-lab. To obtain adequate control DCs for T-cell assays, a fraction of immature DCs from each patient was mock-transfected, that is, electroporated without mRNA. These mock-transfected DC controls (mockDCs) were subsequently matured under the same conditions as the mRNA-transfected DCs. To measure transfection efficiency, DCs were electroporated in separate experiments with enhanced green fluorescent protein (EGFP) mRNA, instead of tumor-mRNA. mRNAs for EGFP and hTERT (Human Telomerase Reverse Transcriptase) were synthesized as described earlier. 15 In DCs transfected with hTERT-mRNA, we measured telomerase activity in a TRAP assay (Telomeric Repeat Amplification Protocol), as described previously. 
Generation of T-cell responses in vitro
PBMCs were isolated from peripheral blood by centrifugation over Lymphoprep (Axis-Shield, Oslo, Norway) and frozen for storage at liquid nitrogen. Thawed PBMCs were plated in 24-well plates (1.5-2 Â 10 6 c/w) and stimulated with irradiated (30 Gy) autologous tDCs (1-2 Â 10 5 DC/w). PBMCs (mostly T cells) were then restimulated weekly (max 1.5 Â 10 6 c/w) with tDCs. Prior to the first stimulation (day 0), PBMCs from patients I-III were divided into two groups. Group A (TcA) was cultured without supplemented cytokines until 3 days after the second stimulation (day 10), subsequently receiving IL-2 (10 U/ml) and IL-12 (100 pg/ml). Group B (TcB) received IL-2 and IL-12 at the same concentrations from day 1. For patients III-IV, one fraction of PBMCs was depleted of CD25 þ cells on day 0, by use of Dynabeads coated with antiCD25 (Dynal, Oslo, Norway). All PBMCs/T cells were cultured in X-Vivo 15 medium (Cambrex Bio Science) supplemented with gentamicin and 5% human serum. In T-cell assays, human serum was omitted from the culture medium.
Isolation of CD4
þ or CD8 þ T cells and blockage of HLA class I or II
CD8
þ T cells were isolated by positive selection using Dynabeads coated with antiCD8 (Dynal). CD4 þ T cells were isolated by depletion of CD8 þ cells. The phenotype of isolated T cells was confirmed by flow cytometry. The following monoclonal antibodies (mAbs) were used in blocking experiments, each at 10 mg/ml: W6/32: (anti-HLA class I; hybridoma cells from American Type Culture Collection, Rockville, MD, USA); anti-HLA-DR (Becton Dickinson); FN81: (anti-HLA-DQ; gift from Dr S Funderud, The Norwegian Radium Hospital) and 22C1 (anti-HLA-DP; gift from Dr S Funderud).
T-cell proliferation assay
T cells were seeded in 96-well U-bottomed microtiter plates, generally at 3-5 Â 10 4 cells per well (c/w). Irradiated (30 Gy) tDCs and mockDC controls were used as APCs at an APC:T-cell ratio of 1:10. Negative controls with T cells only and positive controls with T cells þ mockDCs þ Staphylococcus enterotoxin C 3 (SEC 3 ; Toxin Technologies) were included. T cells were tested for proliferation at each tDC stimulation, subject to availability of cells. Proliferation was generally measured at day 3 after labelling with 3.7 Â 10 4 Bq [ 3 H]thymidine (Laborel, Oslo, Norway) overnight before harvesting. In the first proliferation assay, seeded with freshly thawed PBMCs, labelling and harvesting were usually performed at day 6 and 7, respectively. T-cell proliferation assays were performed in triplicates or hexaplicates.
Interferon-g ELISPOT assay
Interferon-g (IFNg) ELISPOT assays were performed essentially as described previously. 16 Responder T cells were seeded as duplicates at three different concentrations. As APCs, irradiated (30 Gy) tDCs and mockDCs were added at a fixed concentration (4 Â 10 3 DC/w), kept constant through all three T-cell concentrations. Negative controls with T cells only and positive controls with T cells þ mockDCs þ SEC 3 were included. To ensure reliable and unbiased ELISPOT counts, spots were enumerated using an automated ELISPOT counter (Carl Zeiss Vision, Oberkochen, Germany) at The National Hospital, Oslo.
Bioplex cytokine assay
Supernatants were harvested from triplicate T-cell cultures at day 3 and analyzed by Bioplex cytokine assays (Bio-Rad Laboratories, Hercules, CA), according to the manufacturer's protocol. We analyzed the supernatants for IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, TNFa, GM-CSF, IFNg, macrophage inflammatory protein 1b(MIP1b), and monocyte chemoattractant protein 1 (MCP-1). Kits for all cytokines were obtained from Bio-Rad Laboratories.
Statistical analysis
To determine if a proliferation response was significant, we applied Student's t-test for independent samples (SPSS for Windows, SPSS Inc.), comparing T-cell proliferation counts for tDCs and mockDCs. Cytokine concentrations measured by Bioplex were compared by one-way ANO-VA (SPSS). In the ELISPOT assays, the different T-cell concentrations were analyzed together by two-way ANOVA (SPSS). A proliferation, cytokine, or ELISPOT response was considered significant only if Po.05. Proliferation results are displayed as mean counts per minute (cpm)7standard error of the mean (SEM).
Results
Tumor-RNA evaluation
In the melanoma DC vaccine, high-quality mRNA is of fundamental importance, as all relevant tumor antigens are derived from the extracted tumor-mRNA. To obtain extensive information on the extracted RNA, we analyzed RNA samples from patients I, II, III and V on an Agilent Bioanalyser as well as by conventional agarose gel electrophoresis. Results of agarose gel electrophoresis (not shown) were in accordance with Bioanalyser results in all RNA preparations.
Results of Bioanalyser evaluation assays from representative RNA preparations are shown in Figure 1 . For control of RNA preservation after total-RNA extraction, we analyzed the total-RNA samples for intact rRNA peaks and for high 28S/18S rRNA ratios. Figure 1 shows an example of well-preserved total-RNA (a) as well as highly degraded RNA (b). As demonstrated, degradation of RNA is easily detected. With this method of quality control, samples unsuited for vaccination can be identified. In a series of 25 biopsies, only one tumor biopsy (b) with highly degraded RNA was found. This biopsy, which originated in an external hospital, had not been cut into smaller pieces before transfer to RNA later, even though the biopsy diameter was larger than recommended. Even after purification of mRNA, a considerable fraction of RNA is still rRNA (Fig 1c,d) . Degraded RNA, visualized as broad peaks to the left on the Bioanalyser graphs (Fig  1a) , has, however, been removed by purification. Any contaminating traces of DNA also appear to be eliminated by the purification step (data not shown).
The amount of mRNA successfully being transfected into each DC can be assumed to closely correlate with mRNA concentration during electroporation. We (c, d) Purified mRNA preparations from patients I and V. Intact rRNA forms distinct 18S and 28S rRNA peaks. In total RNA preparations, well-preserved RNA is also indicated by a high 28S/18S ratio (a). Highly degraded and hence short RNA fragments form a broader top to the left (a). In the Bioanalyser graphs, rRNA fractions are displayed as peaks on top of the broader mRNA smear. The rRNA component is estimated by marking out the rRNA peaks, and the mRNA content is estimated by subtracting the rRNA component from the measured total-RNA concentration (c, d). The left end peak on all diagrams represents the assay standard (a short DNA fragment).
therefore calculated the amount of mRNA available for transfection based on Bioanalyser estimates of mRNA content in the purified RNA samples. The Bioanalyser estimates were made according to the manufacturer's protocol, as described in Figure 1 . mRNA concentration during electroporation ([mRNA] electrop ) was calculated. Tumor weight before RNA extraction was also registered and used for calculation of mRNA yield per mg tumor. The average mRNA yield was 195 ng mRNA/mg tumor (range 90-350 ng/mg), and the average [mRNA] electrop was 47 mg/ml (range 16-110 mg/ml) ( Table 1) . Finally, the number of DCs during electroporation was registered and related to mRNA amount (Table 1) .
DCs -flow cytometry evaluation
DCs from each patient were stained for flow cytometry by a panel of DC phenotype markers as well as markers for T cells, B cells, monocytes and NK cells. Flow cytometry stainings from a representative patient (patient II) are shown in Figure 2 . Cells distributed like DCs on FSC/ SSC dot plots were gated (region R1, Fig 2a) and regarded as a DC population. Table 2 shows the expression of DC phenotype markers for tDCs and mockDCs in all six patients after DC maturation. The DC population consisted of two subsets: CD83 þ CD14 À cells and CD14 þ CD83 -cells (Fig 2b) . Both subsets expressed HLA class II and costimulatory molecules CD80 and CD86, but expression was higher in the CD83 þ subset (Fig 2c) . Cells outside region R1 mainly consisted of monocytes, T cells and NK cells (data not shown). There was some variation between the different patients both with regard to DC phenotype and presence of other cell types. Importantly, there were no substantial differences between tDCs and mockDC controls in any patient. This held true both with regard to fraction of DCs, phenotype of DCs and the presence of the other cell types.
DC transfection
The method of transfection was first established with a 2-mm (400 ml) electroporation cuvette. 15 In full-scale vaccine productions, it is desirable to use a larger cuvette to limit the number of electroporations, thereby reducing risk of infection and RNA degradation. Efficiency of RNA transfection has repeatedly been evaluated by transfection with EGFP mRNA. A representative EGFP-transfection experiment is shown in Figure 3a , comparing 2-mm (400 ml) and 4-mm (800 ml) cuvettes with optimized settings. As demonstrated, we obtain improved DC survival with the larger cuvette, while retaining high efficiency of transfection (90-99% EGFP-positive DCs, high mean EGFP expression).
Quality controls for documentation of tumor-RNA expression in tDCs have to date not been available. Each single tumor antigen will be present in minute concentrations in the tDCs. To address this problem, we added a defined amount of synthetic mRNA for human telomerase reverse transcriptase (hTERT), a common tumor antigen, to the melanoma RNA prior to transfection. As shown in Figure 3b , this allows for documentation of protein expression by measuring enzymatic activity in the TRAP assay (Telomeric Repeat Amplification Protocol). 15 Enzymatic activity falls to background levels when hTERT concentration during electroporation is reduced to 5 mg/ml. This explains why hTERT acitivity cannot be measured in DCs transfected with tumor-RNA only (Fig 3b) .
T-cell responses
Successful melanoma vaccination will depend on the ability of the tDCs to elicit T-cell responses specific for antigens encoded by the transfected mRNA. To examine whether such T-cell responses could be induced in vitro, we stimulated PBMCs from six advanced melanoma patients with autologous DCs transfected with autologous tumor-mRNA (tDCs). Stimulations with tDCs were carried out weekly. T cells were tested for response to tDCs and mockDCs by T-cell proliferation assays. To possibly increase the sensitivity of our test system, we divided the PBMCs from patient I-III into two groups. T-cell group A (TcA) was cultured without external cytokines (IL2/IL12) until 3 days after the second tDC stimulation (i.e. day 10), while group B was cultured with cytokines from day 1.
Representative proliferation data are shown in Figures  4 and 5 . Prior to the in vitro stimulations there was, except in patient VI, hardly any proliferation to tDCs or mockDCs at all, compared with the PBMC alone a RNA from patients IV and VI were evaluated by agarose gel electrophoresis only. b The rRNA percentage and amount of mRNA in purified mRNA samples were estimated in Bioanalyser assays as described in Figure 1 . controls. In vitro restimulations resulted in considerable T-cell proliferation to both tDCs and mockDCs. In all six patients, a stronger response was obtained with tDCs, indicating that a component of responding T cells was specific to antigens encoded by the transfected mRNA. The mean proliferation counts to tDCs and mockDC controls were compared. A statistically significant proliferation to tDCs was first demonstrated in patients I and III after three previous stimulations (prestim), in patient II after four prestim and in patient IV (CD25-depleted cells, see below) after five prestim. In all these patients, T-cell responses specific to tDCs were also detected after further restimulations. Concerning the effect of IL2/IL12 in culture, the tDC-specific responses were generally more evident for TcA than TcB. To examine the possible suppressive effect of regulatory CD25 þ T cells, we performed a depletion of CD25 þ cells prior to the first stimulation in patients III and IV. In patient III, the CD25-depleted T cells (TcBdepl) proliferated vividly in culture, while the nondepleted T cells (TcA and TcB) only just survived. Proliferation specific to tDCs was demonstrated after three prestim in TcBdepl (Fig 4c) and TcA (data not shown), and after four prestim in TcB (data not shown). Proliferation counts were considerably increased in TcBdepl. In patient IV, only the CD25-depleted T cells survived in culture.
Contrary to patients I-IV, in patients V and VI, tDCspecific T-cell responses were detected without the requirement of several in vitro restimulations. In patient V, high tDC-specific proliferation was demonstrated after only one prestim (Fig 5a) . In patient VI, we detected moderate T-cell proliferation specific to tDCs even in freshly thawed PBMCs (Fig 5b) . After in vitro restimulations, significant tDC-specific responses (Po.01) with higher proliferation counts were demonstrated (data not shown). In vitro generation of new T-cell responses against autologous antigens generally requires several restimulations. The data therefore suggest that patients V and VI have spontaneous in vivo immune responses against antigens encoded by the transfected tumormRNA.
T-cell responses in patients I and II were further studied by IFNg ELISPOT and by measurement of multiple cytokines in Bioplex supernatant assays. For Patient II, IFNg ELISPOT was performed on T cells prestim Â 5 and on freshly thawed PBMCs. The assay demonstrated a significant tDC-specific response only in prestim T cells, with an estimated responder frequency of 25 spots/10 4 T cells (P ¼ .027; data not shown). In Bioplex assays for patient II, we found tDC-specific secretion of a wide range of cytokines, including the Th1-associated cytokines IFNg and TNFa, the proinflammatory chemokines MIP-1b and MCP-1 and the Th2-associated interleukins IL-5, IL-6, IL-10 and IL-13 ( Table 3) . As would be anticipated from the proliferation assays shown above, even mockDCs induced considerable cytokine secretion, compared with T cells only (T only) controls.
In patient I, we studied CD8 þ and CD4 þ T cells separately after positive selection/depletion. Specific proliferation to tDCs was demonstrated for both CD4 þ (not shown) and CD8 þ T cells (Fig 6a) . A specific CD4 þ T cell response was also demonstrated in IFNg ELISPOT (Fig 6b) . For CD8 þ T cells, the IFNg ELISPOT was negative (data not shown). These observations were confirmed by Bioplex cytokine measurements (Table 3) . In both nondepleted T-cell cultures (allTc) and in CD4 þ
and CD8
þ cultures, we demonstrated significant tDCspecific secretion of IL-5, IL-6, IL-13, and MIP-1b. Specific TNFa-secretion, in low concentrations, was detected only in allTc and CD8 þ T-cell cultures. Notably, gINF secretion was found only in allTc and CD4 þ cultures, not in CD8 þ cell cultures (Table 3) . No secretion of IL-4, IL-10, IL-12 or MCP-1 was detected.
As shown in Figure 6a -c, the CD4 þ and CD8 þ T-cell responses could be blocked by antibodies to HLA class II and HLA class I, respectively. Blockage was demonstrated in T-cell proliferation (Fig 6a) , IFNg ELISPOT (Fig 6b) and Bioplex cytokine assays (Fig 6c) . Secretion of all cytokines detected (Table 3 ) was successfully blocked, as shown for three representative cytokines in Fig 6c. The mockDC responses, which were demonstrated in both CD4 þ and CD8 þ T-cell populations, were also blocked by antibodies to HLA (Fig 6a,c) .
Discussion
In this report, we have demonstrated the feasibility of producing an individualized melanoma vaccine consisting of DCs transfected with autologous tumor-mRNA. The vaccine basically relies upon the ability of the tDCs to elicit immune responses specific to antigens derived from the transfected tumor-mRNA. Previously, we had found that such responses could be initiated in vitro for healthy Cells distributed like DCs in FSC/SSC dotplots were gated as shown in Figure 2 (region R1). The percentage of cells in DC region R1 and the expression of DC phenotype markers within R1 are given. hTERT-mRNA at three concentrations (5/50/500 mg/ml), purified RNA from solid melanoma (SM) or a melanoma cell line (FM3), and SM-or FM3-RNA combined with hTERT-mRNA (500 mg/ml). Negative controls with mock-transfected or nonelectroporated DCs were included. Telomerase activity was measured in TRAP-assays 48 h after transfection. Bars represent mean telomerase activity 7SEM from triplicate TRAP-assays.
donors using synthetic telomerase (hTERT) mRNA or mRNA from allogenic prostate cancer cell lines. 15, 16 In the present paper, we test these concepts in the clinical setting of melanoma patients. Going from model systems to an autologous system represents several new challenges. First, the number of potential antigens in an autologous melanoma is most likely much lower than in an allogenic cell line. Second, the source of tumor-mRNA is limited. Third, as the mRNA is obtained from solid tumor, initial preservation and extraction of RNA is more complex, and mRNA is more subject to degradation. Fourth, in a full-scale vaccine production, considerably higher numbers of DCs need to be transfected, resulting in profound dilution of mRNA during electroporation. In the previous hTERT transfections, only 10 5 -10 6 cells were mixed with pure hTERT-mRNA at about 100-200 mg/ml. By contrast, in these full-scale melanoma mRNA transfections, 3.8 Â 10 8 -1.9 Â 10 9 DCs were mixed with various mRNA fragments coding for large numbers of antigens, collectively amounting to only 16-110 mg/ml. Accordingly, each antigen represented in the total melanoma mRNA mix was present in minute concentrations compared with the hTERT-mRNA previously tested. Finally, the vaccination trial is to be conducted in patients with advanced melanoma (stage IV). Contrary to healthy donor experiments, the T cells from patients with advanced disease may be strongly influenced by previous treatment as well as tolerance induction and tumor induced general immunosuppression.
In spite of these a priori biological concerns, our results demonstrate that the tDCs are in fact able to elicit patient immune responses specific to antigens derived from the transfected melanoma mRNA. The nature of the autologous antigens recognized will probably differ considerably between patients, and it is beyond the scope of the present work to characterize the specificity of the T-cell response. Evidently, the minute amounts of tumormRNA successfully reaching into the DCs result in protein production, and new peptides containing immunogenic autologous antigens are presented on HLA molecules on the DC surface. Moreover, specific cellular responses have been demonstrated for all six patients tested. The high in vitro success rate is encouraging with regard to a vaccination trial.
Furthermore, the results (Fig 5) suggest that patients V and VI have been spontaneously primed in vivo to antigens encoded by the transfected mRNA. This provides interesting evidence that antigens presented by the tDCs after transfection are indeed relevant to the antitumor immune response. As mentioned in the Introduction, there have been several reports of spontaneous immune responses in malignant melanoma, and also evidence for correlation with prolonged survival. Interestingly, patient V had a story of protracted stable disease on repeated radiological and clinical examinations, despite extensive lymph node and pulmonary metastases.
The T-cell response generated through repeated in vitro tDC stimulations appears to consist of two components, a tDC-specific component and a background T-cell response against mockDCs. The latter T-cell response may represent an autologous mixed lymphocyte reaction (AMLR), triggered by effective presentation of autologous antigens present in DCs regardless of transfection. DCs have long been assumed to be the prime triggers of AMLR. 21 In our restimulation cultures, potential AMLR antigens are effectively presented by large numbers of mature DCs. Alternatively, the T-cell response to mockDCs could be elicited by foreign antigens engulfed during DC culture. Unlike some previously used DC vaccines, 12 no FCS or human serum was present in our DC cultures. This points to epitopes derived from the supplemented cytokines or from proteins in the Cellgro DC medium as potential sources of the background response. Clearly, these two explanations to the observed background response, AMLR and foreign antigens, are not mutually exclusive. In the in vivo vaccine setting, T cells stimulated by mockDCs could in any case exert an important regulatory influence on the vaccine response, as has been assumed with regard to AMLR in conventional inflammatory conditions. [22] [23] [24] The DC vaccine could also result in expansion of autoreactive T cells recognizing transfected antigens. Accordingly, patients should be monitored carefully with respect to potential autoimmune side effects.
The phenotyping of the mature DCs demonstrated that the clinical scale DC preparations consisted of two phenotypically distinct populations (Table 2/ Fig 2) . Priming of T cells by the two different DC populations could result in different polarization of the responding T cells. 25, 26 The Bioplex results show that a broad spectrum of cytokines were produced in the in vitro generated T-cell response. Moderate amounts of IFNg and TNFa were measured, indicating that some of the responding cells belong to the Th1 subset. Moreover, we detected the proinflammatory CC chemokines MIP-1b and MCP-1, which are known to be potent chemoattractors of T cells and monocytes. These cytokines may promote the creation of an inflammatory environment needed for tumor eradication. 27 A more prominent feature, however, was the high concentration of the Th2 cytokines IL-5 and IL-13. Although IL-4 was not detected, these results suggest a dominating Th2 profile. Interestingly, the use of a conventional set of cytokine assays for Th1/Th2 evaluation, that is, IFNg/IL4, would have resulted in the opposite conclusion. It is thus unclear what the Th2 cytokine profile observed here will mean in a vaccine trial, but generally Th2 type responses are not desirable in this clinical setting. One explanation for the broad cytokine profile may be that during the in vitro culture, all tDCs are in the position to interact with T cells. By contrast, after intradermal vaccination, only a small fraction of the injected DCs will reach the lymph node, preferably those with a phenotype facilitating migration. 28, 29 The results from experiments with isolated CD4 þ and CD8 þ T cells in patient I show that both CD4 þ and CD8 þ tDC-specific T cells are activated in vitro. The Tcell responses are dependent on HLA classI/II interaction, as demonstrated by blocking of proliferation, IFNg ELISPOT and cytokine production. Interestingly, we found that CD8 þ T cells, although clearly responding by proliferation and production of multiple cytokines, appeared not to secrete IFNg in detectable amounts. This explained why IFNg ELISPOT was negative for the CD8 þ T cells, contrary to the CD4 þ T cells. All tumor-associated antigens in the vaccine are derived from the extracted mRNA, and high-quality mRNA is hence essential. In previous DC vaccine trials based on RNA as the source of antigen, RNA evaluation has been restricted to conventional electrophoresis and spectrophotometer analysis. Applying the Bioanalyser technique, we obtain more extensive information on RNA quality. Furthermore, quantitative assessments of mRNA can be made. Our evaluation results show that by the applied methods for RNA extraction, we obtain reproducible quantities of mRNA of satisfactory quality. The results also demonstrate that degraded RNA can easily be detected. As illustrated by the example of highly degraded RNA (Fig 1b) , adequate initial handling of biopsies is instrumental for the use of autologous tumor-RNA.
The Bioanalyser evaluation will allow us to look for correlations between vaccine response and mRNA The concentration of multiple cytokines in supernatants from T-cell cultures was measured by Bioplex (patients I and II). T cells (T) were stimulated with tDCs or mockDCs. For patient II, we studied TcA and TcB, cultured with IL-2/IL-12 from days 3 and 10, respectively. For patient I, we studied isolated CD4 + and CD8 + T cells, as well as complete T-cell cultures (allTc). Supernatants were collected from triplicate cell cultures, each supernatant being kept separate through T-cell stimulation and Bioplex assays. Mean concentration for all detected cytokines is displayed. Concentrations significantly higher (Po.05) in tDC than mockDC controls are shown in bold font. No significant IL-4 or IL-12 was detected (data not shown).
quality/quantity. In the vaccine trial, we will also relate vaccine responses to DC phenotype. Inadequate DC characterization for each included patient has made interpretation and comparison of several previous DC trials difficult. 30 In our previous model systems for DC generation from healthy donors, a high component of
CD14
þ cells was not observed. 16 The component of CD14 þ cells found in full-scale prepararations from melanoma patients could be due to a higher concentration of cells during culture. This may lead to exhaustion of IL-4 and impaired differentiation of monocytes into DCs. We are continuously optimizing conditions for DC cultures, aiming to produce homogenous CD83 þ CD14 -populations for all individual patients. In a vaccine trial, proper immunomonitoring will be essential, also for interpretation of clinical observations. 30 As responses in this vaccine approach could be directed to any of a broad array of unknown transfected antigens, testing with known melanoma antigens would be of limited value. We will accordingly test primarily for responses against the vaccine itself, using mockDCs as a negative control. Based on the observation in the present communication, supplementing IL-2 to the cultures may result in increased background responses, masking the specific response to tDCs. Although very preliminary, the data from patients III and IV indicate that in some patients regulatory CD25
þ CD4 þ T cells may suppress proliferation to tDCs in cultures.
Since regulatory T cells may play an important role in patients with advanced cancer, this possible effect will be systematically explored as part of our immunomonitoring in cancer vaccine trials. Currently, we are preparing a new vaccine trial combining autologous tumor-mRNA with synthetic hTERT-mRNA. In this trial, protein expression in DCs after transfection will be documented by measuring enzymatic activity in the þ T cells isolated after three prestim (patient I). The T cells were stimulated with tDCs and mockDCs. mAbs to HLA class I and class II (HLA-DQ, HLA-DP and HLA-DR) were added to CD8 þ and CD4 þ T cells, respectively. AntiHLA-mAbs induced 450% blockage of cytokine secretion to both tDC and mockDC-stimulation. This held true for both CD4 þ and CD8 þ T cells, and for all cytokines measured (see Table 3 ). Representative blockage results from three cytokines (MIP 1b, IL-5 and IL-13) are displayed. As shown blockage is Z68% for MIP-1b and complete for IL-5 and IL-13, compared with background values (T cells only).
TRAP assay, as demonstrated in Figure 3b . In addition, we will measure T-cell responses against DCs transfected with hTERT only.
We conclude that melanoma vaccination with DCs transfected with autologous tumor-mRNA is indeed feasible. The transfected DCs, produced in full-scale preparations, function to elicit cellular immune responses specific to antigens encoded by the transfected tumormRNA. Adequate methods have been established for mRNA extraction and evaluation, full-scale DC generation and transfection, and monitoring of immune responses. Based on this preclinical evaluation, a vaccine trial has been started in patients with advanced malignant melanoma.
